Who Owns Nurofen?

Nurofen operates within Reckitt's sustainability framework, which focuses on environmental responsibility, responsible sourcing, and ethical business practices.

Packaging Sustainability: Reckitt has committed to making 100% of its packaging recyclable or reusable by 2025. Nurofen packaging, including blister packs and bottles, is being redesigned to improve recyclability and reduce plastic content. The brand has introduced recycled content in its carton packaging.

Responsible Sourcing: Reckitt maintains responsible sourcing guidelines for ingredients used in its products, including pharmaceutical-grade ibuprofen. The company works with suppliers to ensure ethical labor practices and environmental standards in ingredient production.

Environmental Compliance: Nurofen manufacturing facilities operate in compliance with environmental regulations and pharmaceutical manufacturing standards. Reckitt has set targets for reducing carbon emissions, water consumption, and waste across its manufacturing operations.

Access to Medicine: Reckitt participates in access-to-medicine initiatives, though Nurofen's primary markets are developed countries with established healthcare systems. The company supports consumer education about responsible pain relief use and ibuprofen safety.

Nurofen has received recognition as one of the UK's most trusted pain relief brands.

UK's Most Trusted Pain Relief Brand: Nurofen has been consistently recognized as one of the UK's most trusted and recommended pain relief brands in consumer surveys and brand tracking studies. The brand's 40-year heritage and market leadership contribute to strong consumer trust.

Product Innovation Recognition: Nurofen Express Liquid Capsules have been recognized within the OTC pharmaceutical industry for innovation in delivery format, offering faster absorption than traditional ibuprofen tablets.

Pediatric Product Recognition: Nurofen for Children has been recognized by healthcare professionals and parenting publications as a trusted ibuprofen product for infants and children, with formulations designed specifically for pediatric use.

Nurofen Specific Pain Products Controversy (2015-2016): In 2015, the Australian Federal Court found that Reckitt Benckiser misled consumers with its Nurofen Specific Pain range, which included products marketed for back pain, period pain, migraine pain, and tension headache. The court found that all products contained identical 342mg ibuprofen lysine doses and were no more effective at treating specific pain types than standard Nurofen. Reckitt was fined AUD $1.7 million and was required to remove the products from shelves. The controversy also led to similar scrutiny in the UK, where the Advertising Standards Authority (ASA) ruled against Nurofen's targeted pain advertising.

ASA Advertising Rulings: The UK Advertising Standards Authority has issued multiple rulings against Nurofen advertising claims over the years, including claims about faster action, longer lasting relief, and superior efficacy of targeted formulations. These rulings have required Reckitt to modify its advertising claims and marketing materials.

NSAID Safety Concerns: As an NSAID, ibuprofen carries known risks including gastrointestinal bleeding, cardiovascular events, and kidney problems with prolonged use or in patients with certain conditions. Nurofen packaging includes warnings about these risks, and regulatory agencies monitor NSAID safety. The brand has faced scrutiny over whether its marketing adequately communicates these risks to consumers.

Codeine Regulation Impact: Nurofen Plus, which contains codeine, has been affected by regulatory changes restricting codeine availability. In 2018, Australia reclassified codeine-containing products to prescription-only, effectively removing Nurofen Plus from over-the-counter sale in Australia. The UK has also increased scrutiny of codeine-containing OTC products.

Competition from Generic Ibuprofen: Nurofen faces ongoing competitive pressure from generic and private label ibuprofen products, which are significantly cheaper. Consumer organizations and healthcare professionals have frequently highlighted that generic ibuprofen is pharmacologically equivalent to Nurofen, creating challenges for the brand's premium pricing strategy.